logo-loader
viewTonix Pharmaceuticals

Tonix Pharmaceuticals forms second research collaboration with Massachusetts General Hospital

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Lederman tells Proactive the clinical-stage biopharmaceutical company has signed a second research collaboration agreement with Massachusetts General Hospital.

Dr Lederman says while the first collaboration is centered on heart transplantation, the second focuses on developing its antibody TNX-1500 to prevent and treat kidney transplant rejection.

Quick facts: Tonix Pharmaceuticals

Price: 0.8777 USD

NASDAQ:TNXP
Market: NASDAQ
Market Cap: $231.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tonix Pharmaceuticals named herein, including the promotion by the Company of Tonix Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genel Energy now more ambitious and ready to grow in 2021, after 'building...

Genel Energy PLC's (LON:GENL), Bill Higgs speaks to Proactive London about their latest trading and operational result. Higgs explains how 2020, despite being a tough year, 'set the foundation for what's ahead', and now in a position to grow in 2021, with a twelve-well drill campaign among...

3 hours, 9 minutes ago

2 min read